TABLE 3.
Effects of the selected compounds on pharmacoresistant P. falciparum isolatesa
| Patient's country of origin | IC50 (nM)
|
|||||
|---|---|---|---|---|---|---|
| CQ | Qui | Cyc | E10 | G5 | G25 | |
| Comoros | 147 (R) | 123 | 24 | 41 | 7.7 | |
| Comoros | 615 (R) | 146 | 9 | |||
| Senegal | 165 (R) | 193 | 36 | 785 | ||
| Gabon | 250 (R) | 13,100 (R) | 460 | 31 | ||
| Côte d'Ivoire | 270 (R) | 153 | 31,700 (R) | 743 | 111 | 20 |
| Côte d'Ivoire | 656 (R) | 357 | 1,057 | |||
| Côte d'Ivoire | 1,260 (R) | 277 | 300 | |||
| Guinea | 725 (R) | 1,250 (R) | 729 | 66 | 12 | |
| Burkina Faso | 730 (R) | 300 | 3,083 (R) | 1,530 | ||
a
Suspensions of P. falciparum isolates were incubated for 24 h at an initial parasitemia of 0.1 to 1% and at 2.5% hematocrit in the presence of the indicated drugs. See footnote a to Table 2 for abbreviations.